cholestatic diseases
Conditions
Interventions
Experimental group:Danning tablets combined with ursodeoxycholic acid
Sponsors
Hunan Provincial People Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Inpatients who sign informed consent forms; (2) Age range: 18-65 years old gender not limited; (3) ALP exceeds the normal upper limit by 1.5 times and GGT exceeds the normal upper limit by 3 times; (4) According to traditional Chinese medicine it is classified as damp heat stagnation type: meeting two criteria (jaundice rib pain bitter mouth yellow urine constipation); Satisfy 1 condition (pale red tongue thin yellow and greasy tongue coating number of wet veins); (5) Individuals with good main organ function and able to tolerate treatment; (6) Good compliance family members willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: (1) Combination of pharmacologic liver injury autoimmune hepatitis viral hepatitis A B C and E; (2) Patients with combined liver cancer hepatic encephalopathy as well as severe primary diseases of the heart brain kidneys lungs endocrine system blood metabolism and gastrointestinal tract or psychiatric patients; (3) Individuals with creatinine (Cr) levels exceeding the upper limit of normal range; (4) Individuals who use medication for weight loss alcoholism or drug addiction; (5) According to traditional Chinese medicine it is classified as non damp heat stagnation type; (6) Pregnant women breastfeeding women or those preparing to conceive in the near future as well as those using estrogen contraception; (7) Individuals with allergic constitution and allergies to multiple drugs as well as components of this medicine or prescription; (8) Those with critical illness who find it difficult to accurately evaluate the effectiveness and safety of drugs; (9) Patients are unwilling to cooperate with partners; (10) Individuals with mental illnesses who cannot cooperate with regular medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunoglobulin M;liver function;total cholesterol; | — |
Secondary
| Measure | Time frame |
|---|---|
| hyaluronidase;Type III procollagen;liver fibrosis indicators;laminin;liver stiffness;Type IV collagen; | — |
Countries
China
Contacts
Public ContactYa Peng
Hunan Provincial People Hospital
Outcome results
None listed